RecruitingNot ApplicableNCT05743283

Efficacy of SynEx Wound Rinse in Civilian Surrogates of Combat Injury Wounds

Efficacy of SynEx™ Wound Rinse in Civilian Surrogates of Combat Injury Wounds


Sponsor

Synedgen, Inc.

Enrollment

100 participants

Start Date

Apr 12, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this interventional study is to compare SynEx Wound Cleanser with the current routine care (Saline) in traumatic wounds. Participants with gunshot, penetrating or burn wounds who participate will be asked to attend up to four study visits, use the assigned wound cleanser and complete brief surveys about their healing and well-being related to the wound healing.


Eligibility

Min Age: 18 Years

Exclusion Criteria12

  • Penetrating, puncture or laceration wounds: stage II-III (partial to full thickness loss of dermis) excluding diabetic or venous wounds, and pressure ulcers and perforated wounds (except gunshot wounds) and wounds with exposed bones, facia or muscle.
  • Gunshot wounds (GSW): Grade I - II on the Red Cross Classification of War Wounds6 (diameter of entry + exit wounds < 10 cm, wound cavity or not, no fracture or fraction without clinically significant comminution). Non-penetrating, penetrating, or perforated GSW are included. GSW with suspected vascular injuries or nerve damage are excluded.
  • Burns: partial thickness injury ≤ 9% TBSA. Thermal burn from flame or scald, chemical burns, and electrical burn are included. Radiation and frostbite burns are excluded.
  • Males and females ≥18 years old.
  • Has access to a computer or mobile device for telepresence visits.
  • Able to give informed consent and willing to comply with all required study procedures.
  • Any wound likely to require irrigation and debridement in an operating room (OR) setting.
  • Concomitant processes sustained contemporaneously with the dermal injury (e.g., inhalational injury requiring ventilation, electrical injury with cardiac damage or arrhythmia, sepsis, traumatic brain injury, other serious or unstabilized organ damage from trauma, etc.).
  • > 72 hrs from initial injury.
  • Pregnant or lactating females.
  • Patients with known allergy(ies) to any of the components of the study irrigation system.
  • Patients who are considered by the investigator for any reason to be an unsuitable candidate.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICESynEx Wound Cleanser

SynEx is a concentrated form of SynePure®, an FDA 510(k) cleared aqueous, osmotically balanced wound cleanser containing patented chitosan derivatives. The ingredients are USP purified water, chitosan arginine (a patented chitosan derivative), sorbitol powder, and betaine. SynEx cleanser is packaged in a collapsible plastic pouch for reconstitution in water before debriding and cleansing a wound.

OTHERSaline

The saline solution is composed of water and salt. It is packaged in a collapsible plastic pouch.


Locations(2)

MedStar Washington Hospital Center

Washington D.C., District of Columbia, United States

Barnes Jewish Hospital

St Louis, Missouri, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05743283


Related Trials